Nexus Surgical and Medicare Ltd Downgraded to Sell Amid Mixed Technical and Valuation Signals

Quality Assessment: Strong Fundamentals Amidst Market Challenges

Nexus Surgical continues to demonstrate robust fundamental strength, particularly in terms of profitability and return metrics. The company boasts an impressive average Return on Equity (ROE) of 31.15%, with the latest quarter (Q4 FY25-26) reporting an even higher ROE of 40.6%. This indicates efficient capital utilisation and strong earnings generation relative to shareholder equity. Additionally, the company’s net sales for the nine months ending March 2026 rose to ₹6.15 crores, while profit after tax (PAT) increased to ₹0.58 crores, signalling positive operational momentum.

Profit before depreciation, interest and taxes (PBDIT) for the quarter reached a peak of ₹0.30 crores, underscoring improving earnings quality. The company’s long-term performance has been market-beating, with a 5-year return of 515.87% compared to the Sensex’s 42.50%, and a 3-year return of 94.00% versus the Sensex’s 18.25%. These figures highlight Nexus Surgical’s ability to generate substantial shareholder value over extended periods.

Valuation: Expensive Despite Discount to Peers

Despite strong fundamentals, Nexus Surgical’s valuation metrics have raised concerns. The stock trades at a Price to Book (P/B) ratio of 5.9, which is considered very expensive, especially for a micro-cap NBFC. This elevated valuation suggests that the market has priced in significant growth expectations. However, the company’s Price/Earnings to Growth (PEG) ratio stands at a low 0.3, indicating that earnings growth is currently outpacing the price increase, which could be a positive sign for value-oriented investors.

Nonetheless, the stock is trading at a discount relative to its peers’ average historical valuations, which somewhat mitigates the valuation risk. The juxtaposition of a high P/B ratio with a low PEG ratio presents a complex valuation picture, where the market’s optimism is tempered by cautious pricing compared to sector benchmarks.

Financial Trend: Positive Earnings Growth but Mixed Returns

Financially, Nexus Surgical has delivered encouraging results in the recent quarter and nine-month period. The company’s profits have risen by 23% over the past year, reflecting operational efficiency and revenue growth. The stock’s one-year return of 12.99% outpaces the Sensex’s negative 8.84% return over the same period, indicating relative strength in a challenging market environment.

Year-to-date (YTD), the stock has gained 10.86%, while the Sensex has declined by 12.88%, further emphasising Nexus Surgical’s resilience. However, the stock’s short-term returns have been less impressive, with a one-week decline of 2.51% and a one-month drop of 3.00%, both underperforming the Sensex’s respective returns of -0.71% and -3.60%. This short-term weakness may have contributed to the reassessment of the stock’s outlook.

Technical Analysis: Downgrade Driven by Softening Momentum

The most significant factor behind the downgrade is the change in technical indicators, which have shifted from bullish to mildly bullish territory. The technical grade downgrade reflects a more cautious market sentiment and a potential slowdown in upward momentum.

Key technical signals present a mixed picture. The Moving Average Convergence Divergence (MACD) remains bullish on both weekly and monthly charts, suggesting underlying positive momentum. However, the Relative Strength Index (RSI) shows no clear signal on weekly or monthly timeframes, indicating a lack of strong directional conviction.

Bollinger Bands are mildly bullish on both weekly and monthly charts, while daily moving averages also suggest mild bullishness. The Know Sure Thing (KST) indicator is bullish weekly but mildly bearish monthly, signalling some divergence in momentum across timeframes. Dow Theory analysis shows a mildly bullish weekly trend but no clear monthly trend, adding to the uncertainty.

Price action has been weak recently, with the stock closing at ₹19.40 on 8 June 2026, down 4.90% from the previous close of ₹20.40. The 52-week high stands at ₹25.50, while the 52-week low is ₹13.26, indicating a wide trading range but recent weakness near the upper end.

Shareholding and Market Capitalisation

Nexus Surgical is classified as a micro-cap stock, with majority shareholding held by non-institutional investors. This ownership structure can contribute to higher volatility and less liquidity compared to larger, institutionally backed companies. Investors should be mindful of this factor when considering exposure to the stock.

Conclusion: Balancing Strong Fundamentals Against Technical and Valuation Risks

The downgrade of Nexus Surgical and Medicare Ltd from Hold to Sell by MarketsMOJO reflects a comprehensive reassessment of the stock’s prospects. While the company’s quality and financial trends remain strong, with impressive ROE and profit growth, the technical indicators have softened, signalling caution among traders and investors.

Valuation remains a key concern, with a high Price to Book ratio suggesting the stock is expensive relative to its book value, despite a low PEG ratio that hints at undervalued growth potential. The micro-cap status and predominantly non-institutional shareholding add layers of risk and volatility.

Investors should weigh the company’s solid long-term fundamentals and market-beating returns against the recent technical weakness and valuation premium. The downgrade serves as a reminder to monitor momentum and price action closely, especially in a sector as sensitive as NBFCs.

Overall, the Sell rating advises caution and suggests that investors consider alternative opportunities within the sector or broader market that may offer a more favourable risk-reward profile.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today